• Profile
Close

Association of immune-related adverse events with nivolumab efficacy in non–small-cell lung cancer

JAMA Oncology Sep 26, 2017

Haratani K, et al. - This study aimed to investigate the association of immune-related adverse events (irAEs) with nivolumab efficacy in non–small-cell lung cancer (NSCLC). In patients with advanced or recurrent NSCLC, development of irAEs seemed associated with survival outcome of nivolumab treatment.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay